BALFAXAR recipients vs. the Kcentra cohort. These observations predict that the. Kcentra subjects carried a higher antecedent risk of TEE
Results showed that treatment with Balfaxar was noninferior to Kcentra. At the prespecified interim analysis, 94.6% of patients in the Balfaxar
Balfaxar demonstrated effective hemostasis in 94.6% of patients versus 93.5% of patients for Kcentra. International Normalized Ratio (INR) reductions and
BALFAXAR vs Kcentra (95% CI for difference). BALFAXAR (N=105), Kcentra (N=103). Decrease of INR to ≤ 1.5 at 30 min, 82 (78.1), 74 (71.8), 6.3% (5.5%, 18.0%)
Balfaxar (prothrombin complex co. Balfaxar demonstrated effective hemostasis in 94.6% of patients versus 93.5% of patients for Kcentra.
List of Anticoagulant reversal agents ; Vitamin K1 phytonadione ; Mephyton phytonadione ; Praxbind idarucizumab ; Kcentra prothrombin complex ; Balfaxar
78.1% of patients receiving BALFAXAR vs 71.8% in the Kcentra group had a reduction in INR to 1.5 at 30 minutes postinfusion in a randomized, controlled trial 1,c. Patients on BALFAXAR had sustained INR reduction to 1.3 for up to 24 hours after infusion1.
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults
then vs than
accept vs expect
alright vs all right
its vs it's
there vs their
waist vs waste
your vs you're, you are